Repligen Beats on Q3 Earnings Sales, Narrows 24 Sales View
| BIIB Stock | USD 158.01 2.01 1.29% |
About 51% of Biogen's investor base is interested to short. The analysis of overall sentiment of trading Biogen Inc stock suggests that many investors are impartial at this time. The current market sentiment, together with Biogen's historical and current headlines, can help investors time the market. In addition, many technical investors use Biogen Inc stock news signals to limit their universe of possible portfolio assets.
Biogen |
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Read at zacks.com
 |
Biogen Fundamental Analysis
We analyze Biogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Biogen is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Biogen Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biogen stock to make a market-neutral strategy. Peer analysis of Biogen could also be used in its relative valuation, which is a method of valuing Biogen by comparing valuation metrics with similar companies.
Peers
Biogen Related Equities
| ABBV | AbbVie | 2.37 | ||||
| PFE | Pfizer | 2.03 | ||||
| MRK | Merck | 1.38 | ||||
| GILD | Gilead Sciences | 1.27 | ||||
| GSK | GlaxoSmithKline PLC | 1.05 | ||||
| NVS | Novartis | 0.74 | ||||
| AMGN | Amgen | 0.71 | ||||
| BMY | Bristol Myers | 0.60 | ||||
| SNY | Sanofi ADR | 0.42 | ||||
| JNJ | Johnson Johnson | 0.80 |
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |